Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
06/2003
06/12/2003US20030109674 Antiinflammatory agents; medical diagnosis; genetic engineered polypeptide
06/12/2003US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/12/2003US20030109576 Tartrate salts of (r) -3-n,n- dicyclobutylamino-8-fluoro-3,4-dihydro-2h-1- benzopyran-5-carboxamide
06/12/2003US20030109570 Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases
06/12/2003US20030109567 Antitumor agent which comprises said compound or a physiologically acceptable salt thereof as an active ingredient.
06/12/2003US20030109565 Administered by any means other than orally, characterized in that it comprises xylitol, and more particularly to an antipyretic preparation characterized in that it consists of an antipyretic and a synergistic amount of xylitol.
06/12/2003US20030109564 Treating: allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
06/12/2003US20030109558 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
06/12/2003US20030109556 Melanocortin receptor ligands
06/12/2003US20030109547 Amidinophenylpyruvic acid derivatives
06/12/2003US20030109545 Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors.
06/12/2003US20030109542 Intermediates and methods of treating a herpesvirus infection, atherosclerosis or restenosis using such compounds or salts.
06/12/2003US20030109541 3-Phenyl-3,7-diazabicyclo[3.3.1] nonane compounds, process for preparing them, pharmaceutical compositions containing them and use thereof to inhibit cardiac arrhythmia
06/12/2003US20030109533 New benzenesulphonamide compounds
06/12/2003US20030109530 Diabetes, insulin resistance, dyslipidemia, obesity, high blood pressure, atherosclerosis, retinopathies and neurodegenerative disorders; synthesis by reacting a biguanide with an aldehyde, semiacetal or acetal in presence of acid catalyst
06/12/2003US20030109527 Novel hydroxy diphenylurea sulfonamides, compositions and intermediates thereof. The hydroxy
06/12/2003US20030109526 Azo amino acids derivatives
06/12/2003US20030109522 Ophthalmologic treatment methods using selective iNOS inhibitors
06/12/2003US20030109521 Aryl substituted thiazolidinones and the use thereof
06/12/2003US20030109517 Azacycloalkanone serine protease inhibitors
06/12/2003US20030109500 Compositions and methods for use in targeting vascular destruction
06/12/2003US20030109497 Novel imidazolidine derivatives, their preparation and their use
06/12/2003US20030109491 Use of heparinoid derivatives for the treatment and diagnosis of disorders which can be treated with heparinoids
06/12/2003US20030109490 Composite stimulating iNOS enzyme which induce immuno-reactant nitric oxide synthesis and process for preparing the same
06/12/2003US20030109463 Novel macrolides
06/12/2003US20030109452 Containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological applications.
06/12/2003US20030109442 Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109436 Wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. DNA sequence codes for cells
06/12/2003US20030109433 Protection against ischemia and reperfusion injury
06/12/2003US20030109430 Immunoassays for human and canine brain natriuretic peptide
06/12/2003US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
06/12/2003US20030109416 methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.
06/12/2003US20030108951 Screening drugs using antigens; suppress gene expression
06/12/2003US20030108928 MID 241 receptor, a novel G-protein coupled receptor
06/12/2003US20030108904 Novel scavenger receptors
06/12/2003US20030108624 Treating micro- and macroangiopathic conditions with a bioflavonoid plant extract as antioxidant along with a neovascular controller as an angiogenesis inhibitor; vision defects; wound healing agents; cardiovascular disorders
06/12/2003US20030108620 Prophylactic treatment of secondary injury of tissue traumatic event, surgery, transplant, nonproliferative tissue, burns, using of 3-methylsulfonyl-4-piperidinyl benzoyl)guanidine methanesulfonate or N,N-dimethylamiloride
06/12/2003US20030108617 Use of a formulation made of or containing at least one dissimilated milk serum
06/12/2003US20030108602 Controlling releasing
06/12/2003US20030108600 Ubidecarenone compositions and capsules containing the same
06/12/2003US20030108593 Reduction inhibitory agent for active oxygen eliminating activity
06/12/2003US20030108540 Inducing apoptosis in tissues; binding antibodies
06/12/2003US20030108539 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
06/12/2003US20030108510 Synergistic mixture of rutin, escin and bufemin; branching of arteries, veins
06/12/2003CA2469524A1 Adipocyte differentiation-related gene and protein
06/12/2003CA2469385A1 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
06/12/2003CA2469227A1 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
06/12/2003CA2469193A1 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
06/12/2003CA2469078A1 Immunotherapeutic methods and systems
06/12/2003CA2468967A1 N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
06/12/2003CA2468927A1 Ring fused pyrazole derivatives
06/12/2003CA2468846A1 Peroxisome proliferator activated receptor agonists
06/12/2003CA2468827A1 Insulin resistance improving agents
06/12/2003CA2468558A1 "compressed annular tablet with molded triturate tablet for oral and intraoral"
06/12/2003CA2467435A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
06/11/2003EP1318150A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
06/11/2003EP1318149A1 Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing them
06/11/2003EP1318147A1 Novel pyrimidine derivative and novel pyridine derivative
06/11/2003EP1318146A1 Process for producing pyrimidine derivative and intermediate thereof
06/11/2003EP1317930A1 Antithrombin for prevention and therapy of vascular proliferative diseases
06/11/2003EP1317924A1 Kit for reducing aching caused by pde-v inhibitors
06/11/2003EP1317922A1 Antipyretic preparation containing xylitol
06/11/2003EP1317540A2 Imidazoline receptor homologs
06/11/2003EP1317531A2 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof
06/11/2003EP1317487A2 Caveolin peptides and their use as therapeutics
06/11/2003EP1317483A2 Variants of allergenic proteins of the group 2 of dermatophagoides
06/11/2003EP1317479A2 Methods and compositions for diseases associated with amyloidosis
06/11/2003EP1317465A1 Purine derivatives
06/11/2003EP1317459A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
06/11/2003EP1317458A2 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2alpha antagonists
06/11/2003EP1317457A2 INTERHETEROARYL 7-OXABICYCLIC 2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F 2$g(a)? ANTAGONISTS
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
06/11/2003EP1317453A1 Isoxazoles and their use as inhibitors of erk
06/11/2003EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317446A1 Oxindole derivatives
06/11/2003EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317443A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317439A1 Acid-sensitive compounds, preparation and uses thereof
06/11/2003EP1317433A2 Inhibitors of glycogen synthase kinase 3
06/11/2003EP1317432A1 Piperidine derivatives for use as 2,3-oxidosqualene-lanosterol cyclase inhibitors
06/11/2003EP1317431A2 Polyarylcarboxamides useful as lipid lowering agents
06/11/2003EP1317428A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors
06/11/2003EP1317424A2 Polyamine analogues as therapeutic and diagnostic agents
06/11/2003EP1317421A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317420A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317417A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317414A2 Gamma-ketoacid dipeptides as inhibitors of caspase-3
06/11/2003EP1317308A2 Reduction of the electrocardiographic ot interval
06/11/2003EP1317289A2 High efficiency cardiac gene transfer
06/11/2003EP1317283A2 Tweak receptor agonists as anti-angiogenic agents
06/11/2003EP1317276A2 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects
06/11/2003EP1317272A2 Composition for improving the cell protection comprising a lipophilic antioxidant an a hydrophilic antioxidant
06/11/2003EP1317266A2 Neuroprotective 2-pyridinamine compositions and related methods
06/11/2003EP1317265A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
06/11/2003EP1317264A2 Combination of lipoic acids and conjugated acids for treating diabetic disorders
1 ... 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 ... 1595